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Summary 
Selective expression of murine cytomegalovirus  (MCMV) immediate-early (IE) genes leads to 
the presentation  by the major histocompatibility complex (MHC)  class I molecule L  a of a 
peptide derived from MCMV IE protein pp89 (Reddehase, M. J., J. B. Rothbard, and U. H. 
Koszinowski.  1989. Nature (Lond.). 337:651). Characterization of endogenous antigenic peptides 
identified the pp89 peptide as the nonapeptide msYPHFMFFNLt76 (del Val, M., H.-J. Schlicht, 
T. Ruppert, M. J. Reddehase, and U. H. Koszinowski. 1991. Cell. 66:1145). Subsequent expression 
of MCMV early genes prevents presentation of pp89 (del Val, M., K. Mfinch, M. J. Reddehase, 
and U. H. Koszinowski.  1989. Cell. 58:305). We report on the mechanism by which MCMV 
early genes interfere with antigen presentation.  Expression of the IE promoter-driven bacterial 
gene lacZ by recombinant MCMV subjected antigen presentation of B-galactosidase to the same 
control and excluded  antigen  specificity. The La-dependent  presence of naturally processed 
antigenic peptides also in nonpresenting cells located the inhibitory function subsequent to the 
step of antigen processing. The finding that during the E phase of MCMV gene expression the 
MHC class I heavy chain glycosylation remained in an Endo H-sensitive form suggested a block 
within the endoplasmic reticulum/c/s-Golgi compartment. The failure to present antigenic peptides 
was explained by a general retention of nascent assembled trimolecular MHC class I complexes. 
Accordingly, at later stages of infection a significant decrease of surface MHC class I expression 
was seen, whereas other membrane glycoproteins remained unaffected. Thus, MCMV E genes 
endow this virus with an effective immune evasion potential. These results also indicate  that 
the formation of the trimolecular complex of MHC dass I heavy chain, ~2-microglobulin,  and 
the finally trimmed peptide is completed before entering the medial-Golgi  compartment. 
T  lymphocytes recognize short peptides derived from an- 
tigenic proteins. These peptides are presented at the cell 
surface  by specialized  molecules encoded in the MHC (reviewed 
in reference 1). There are two classes of MHC molecules that 
present peptides at the cell surface. MHC class II molecules 
present peptides that are derived from proteins degraded in 
endosomal vesicles to CD4 + T lymphocytes, whereas MHC 
class I molecules present peptides from proteins degraded in 
the cytosol to CD8 + T lymphocytes.  For cytosolic antigen 
degradation a nonlysomal proteinase complex encoded in the 
MHC represents a candidate (2-4). Although translocation 
of peptides into the rough endoplasmic reticulum (EIL)  t is 
1Abbreviations used in  this paper: Act  D,  actinomycin  D;  B-gal, 
/3-galactosidase;/3zm,/32-microglobulin;  CH, cycloheximide; ER, endo- 
plasmic reticuhm; HCMV, human cytomegalovirus; IE, immediate-early; 
MCMV,  murine cytomegalovirus; MEF, mouse embryo fibroblasts; p.i., 
postinfection. 
believed to require ATP-dependent peptide transporters (5-7), 
recent evidence indicates that peptide translocation can occur 
independently of ATP (8). x-ray crystallographic analysis of 
an MHC dass I protein has revealed a cleft where peptides 
are bound (9). A block in the secretory pathway prevents an- 
tigen presentation  (10, 11). Indirect evidence points to the 
EtL or c/s-Golgi reticulumAalvage compartment as the place 
of peptide binding (12-14), but subsequent  compartments 
cannot be excluded. Studies on cell lines defective in antigen 
presentation  suggest that only after assembly of the MHC 
class I heavy chain with the peptide and/32-microglobulin 
(/32m)  is  a  stable  trimolecular complex  exported  to  the 
plasma membrane (15, 16). MHC dass I molecules without 
peptide have a different conformation (14, 17,  18) and are 
deficient with respect to surface  transport and stability (15, 19). 
CD8 +  T  lymphocytes that  recognize peptides  derived 
from viral proteins  synthesized in infected cells play a deci- 
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the means to interfere with immune recognition  (listed in 
reference 20). Extensively studied is the interference strategy 
of adenoviruses.  In the case of the tumorigenic  adenovirus 
type 12, the viral protein E1A blocks MHC class I expres- 
sion already at the level of transcription (21, 22). In contrast, 
the E3/19K protein of adenovirus type 2 binds to the MHC 
class I molecule and, by retaining it in the ER/c/s-Golgi com- 
partment,  blocks cell surface expression and antigen presen- 
tation  (23-26). 
Cytomegaloviruses  (CMV)  are  species-specific  herpes 
viruses, which persist in the host for life after infection. Viral 
persistency can take the form of chronic disease,  asymptom- 
atic productive infection,  or even viral latency.  MHC class 
I-restricted T lymphocytes play a prominent protective role 
(reviewed in reference 27). Accordingly, infection of the im- 
mature or immunocompromised host can result in severe CMV 
disease and death. Thus, CMV often causes disease after bone 
marrow transplantation  and represents  the major viral problem 
during the final stages of AIDS, In permissively infected cells, 
CMV gene expression is regulated in a cascade fashion char- 
acteristic for herpes viruses. Viral proteins encoded by genes 
expressed in the immediate-early (IE) phase of infection con- 
trol the activation of early (E) phase genes.  E proteins  are 
required for viral DNA synthesis, which is followed by the 
synthesis of structural  proteins during the late phase of in- 
fection. Studies on murine CMV (MCMV) have revealed that 
CMV also has the capacity to interfere with antigen presen- 
tation  (28).  Recognition by CTL  of the IE protein pp89, 
a nonapeptide of which is presented by the MHC class I mol- 
ecule L d in the BALB/c strain of mice (29-31), is abolished 
after expression of E genes (28). The failure of pp89 presen- 
tation  appeared to be selective in that  MCMV E antigens 
could be presented.  Since pp89 synthesis,  stability, and nu- 
clear  transport  remained  unchanged  in  the  E  phase,  we 
hypothesized that characteristics of the protein or its regula- 
tory function affected pp89 processing during the E phase. 
Here we define the step at which MCMV E gene products 
interfere with the natural  pathway of pp89 processing and 
peptide presentation. First, the inhibition of further glycosy- 
lation indicates that the transport of MHC class I molecules 
through  the Golgi compartment  is generally  inhibited  by 
MCMV E gene functions. Second, because cells with arrested 
transport of MHC class I molecules contain already the cor- 
rectly processed nonapeptide of pp89,  these results suggest 
the ER/cis-Golgi  compartment  represents  the site of anti- 
genic peptide binding  to MHC class  I molecules. 
Materials  and  Methods 
Mice.  BALB/cJ (H-2  d) and BALB/cJ-H-2  din2 (H-2  dm2) mice 
were bred in our own colony under spedfic pathogen-free conditions. 
Cells.  Mouse embryo fibroblasts (MEF) prepared from either 
strain of mice, were used after three in vitro passages for virus in- 
fection and extraction of naturally processed peptides. In some ex- 
periments the SV40-transformed MEF cell line, BALB.SV,  was used 
(31). The cell line P13.1 originates  from the mastocytoma  P815 
cells that were transfected with the lacZ gene encoding ~-gal (32). 
Viruses.  MCMV of the strain Smith (VR-194; American Type 
Culture Collection [ATCC], RockviUe,  MD) was employed as tissue 
culture-grown virus. The MCMV recombinant MCMV lacl was 
constructed essentially  as described for RM408 (33), but using DNA 
of the wild-type strain Smith.  The recombinant  vaccinia viruses 
MCMV-iel-VAC, expressing pp89, and vSC8, expressing B-gal, have 
been described before (34, 35). 
Antibodies.  The following  mAbs were used:  28-14-8s (anti- 
LdoL3, reactive with  aLl L  a molecules) (18); 64-3-7  (anti-Ldc~2, 
specific for  unassembled  L  a)  (18); 34-5-8s (anti-D a)  (HB  102; 
ATCC); K17 217.1.3 (anti-murine  transferrin receptor) (TIB 219; 
ATCC); IM7-8.1E4 (anti-pgpl)  (36). 
Infection Conditions.  Selective  expression of MCMV IE gene 
products was achieved by infection of cells with MCMV in the 
presence of cycloheximide (CH), which was replaced 3 h later by 
actinomycin D (Act D). Controlled  transition  to the E phase was 
achieved by incubating  the ceils in the absence of drugs for varied 
periods of time after removal of CH; IE proteins translated in this 
period activate the transcription  of E genes, until  Act D blocks 
further transcription  (see Fig. 2 A). Infection was performed by 
centrifugation  at 800 g for 30 rain,  to enhance the efficiency by 
a factor of 10-40. 
Isolation of Endogenously Processed  Peptides.  Processed peptides 
were extracted with TFA from whole cells (,~10  s cells per extrac- 
tion)  and tested in a CTL assay as described (31). The protocol 
for peptide extraction  from infected cells mimicked the prepara- 
tion of target calls. Cells were trypsinized at 7 h postinfection (p.i.), 
incubated in suspension for 90 rain at 37~  and then  subjected 
to acid extraction. 
Cytolytic Assays.  For the production  of target ceils, cells were 
labeled with 51Cr for 90 min. Incubation  of labeled P815 cells for 
1 h at 37~  with HPI.C fractions to be tested for the presence 
of biologically active naturaLly processed peptides preceded the ad- 
dition  of polyclonal  pp89-specific CTL  (31). La-restricted and 
B-gal-specific  CTL were generated by in vitro restimulation of spleen 
cells from mice in vivo primed with vSC8 (107 cells/ml in culture 
medium) with 30 Gy-irradiated P13.1 cells (10  s ceUs/ml in culture 
medium), CTL were propagated by weekly restimulations and ad- 
dition  of recombinant  human  Ib2 (100 U/ml). Graded numbers 
of effector cells in threefold dilution steps were used in a standard 
3-h cytolytic assay. Data represent the mean percentage of specific 
lysis from three replicate cultures. The E/T ratio that gave plateau 
lysis with either CTL usually ranged from 50:1 to 5:1, and in some 
of the experiments  only the values of plateau lysis are shown. 
Metabolic Labeling and Immunoprecipitation.  Cells were washed 
three  times in  methionine-free  medium  before incubation  with 
[3SS]methionine (1,200 Ci/mmol; Amersham, Braunschweig, Ger- 
many) at a concentration of 500 #Ci/ml at 37~  for the time indi- 
cated in the figure legends. In pulse-chase experiments, labeled ceils 
were washed in prewarmed complete medium with 10 mM nonla- 
beled methionine and incubated further for the indicated time. After 
washing with PBS, cells (2  x  106) were lysed in 1 ml lysis buffer 
(1% NP-40, 5 mM MgClz, 140 mM NaCI, 20 mM Tris, pH 7.6, 
and 0.2 mM PMSF). Lysates  were cleared by centrifugation at 13,000 
g  for  30  min  and  supernatants  were  stored  at  -20~  After 
preclearing of lysates with protein  A-Sepharose (75 #1 of a 1:1 
buffer/Sepharose slurry),  the addition  of 2 #1 of ascitic fluid for 
45 rain, and the addition of 50 #1 of protein  A-Sepharose for 30 
rain, resulted in quantitative precipitation of the respective antigen. 
To assure quantitative retrieval of immune complexes, the lysates 
were incubated two more times with protein A-Sepharose before 
adding the next  mAb. The Sepharose beads were washed twice 
with the first washing buffer (0.2% NP-40, 10 mM Tris-HC1, pH 
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washing steps with the second (0.2% NP-40,  10 mM Tris-HC1, 
pH 7.6, 500 mM NaC1,  2 mM EDTA) and third washing buffer 
(10 mM Tris-HC1,  pH 7.6).  Immune complexes were eluted by 
incubation with sample buffer and analyzed by 10-15% polyacryl- 
amide gradient gel electrophoresis. 
Endoglycosidase Treatment.  For Endo H (Boehringer, Mannheim, 
Germany) digestion,  the immunoprecipitates bound  to protein 
A-Sepharose beads were resuspended in 50 mM phosphate buffer, 
pH 5.5, with 0.02% SDS, 0.1% NP-40, and 0.2 mM PMSF, and 
heated to 95~  for 4 min. Thereafter, 100 mM 2-ME and 2 mU 
of Endo H were added,  and digests were analyzed by SDS-PAGE 
after incubation for 18 h  at 37~ 
Flow Cytometry.  Trypsinized BALB.SV cells were preincubated 
in 5% goat serum and then stained with hybridoma supematants. 
Bound antibodies were visualized  by addition of fluoresceinated 
goat anti-mouse isotype-specific  (Medac, Hamburg, Germany) or 
anti-rat  IgG antibodies (Southern Biotechnology, Birmingham, 
AL). As negative controls, served cells incubated with the second 
antibody alone.  104 cells were analyzed for each fluorescent  profile 
on a FACScan  IV  |  (Becton Dickinson & Co.,  San Jose,  CA). 
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Figure 1.  Construction of the MCMV recombinant MCMV lacl. The 
HindlII cleavage map of the 235-kb double-stranded DNA genome of 
MCMV is shown at the top and the position of the plasmid  cloned 7.3-kb 
HindlII L fragment is indicated  as a black box (39). The genes and regula- 
tory elements contained in this region are shown below in a schematic 
fashion to indicate the position of the enhancer sequence  (open box), the 
iel gene promoter (boxed  arrow), the transcription direction of genes iel 
and ie2 that start in this fragment, and to indicate their protein products 
pp89 (IE1) and IE2 (37, 38, 40). The two HpaI sites flanking the ie2 pro- 
moter (arrow)  were used to excise  this regulatory element and to replace 
it by a 3.5-kb fragment consisting of the iel promoter upstream of the 
bacterial/acZ gene open reading frame coding for/~-gal. The resulting 
plasmid was then used to isolate the MCMV lacl recombinant generated 
by homologous  recombination  after  cotransfection  of  cells  with linear  DNA 
of the modified HindlII  fragment and MCMV strain Smith DNA. 
Results 
Lack of Selectivity in the Inhibition  of Antigen Presentation  by 
MCMV  E  Gene Products.  During  the E phase of MCMV 
replication, the presentation of the IE1 antigen pp89 by the 
MHC class I molecule L a is prevented. We reasoned that if 
pp89 was the only target of inhibition,  then intrinsic prop- 
erties of pp89  should account for the lack of presentation. 
Other MCMV IE proteins besides pp89 encoded by gene 
iel  are IE2  and IE3,  encoded by genes ie2 and  ie3,  respec- 
tively (37, 38). The corresponding continuous open reading 
frames were cloned in recombinant vaccinia viruses (M. Mes- 
serle, unpublished data).  No CTL could be induced by the 
established procedures  (34),  and it was concluded that  IE2 
and IE3 do not represent antigens for BALB/c CTL. An un- 
related protein of proven antigenicity for the BALB/c strain 
is  the  bacterial  protein  ~/-galactosidase  (/3-gal),  which  is 
presented by the MHC  class  I  molecule L d (32).  The lacZ 
gene has been successfully integrated into  the MCMV  ge- 
home (33). We constructed an equivalent MCMV-Smith strain 
recombinant. A short deletion encompassing the ie2 promoter 
was created and the lacZ gene under control of the iel  pro- 
moter was  inserted  into  this  position,  resulting  in  the ex- 
pression of lacZ as an IE gene by recombinant MCMV lacl 
(Fig.  1). 
Presentation to CTL of pp89 and B'gal was tested in cells 
infected with MCMV  lacl  under  the conditions described 
before (28), and is represented schematically in Fig. 2 A. In- 
fection of cells in the presence of the protein synthesis inhib- 
itor CH  results  in enhanced  transcription  of IE genes,  in- 
cluding gene iel  encoding pp89.  After replacement of CH 
by the inhibitor of transcription Act D, IE mKNA is trans- 
lated, leading to enhanced and selective IE protein synthesis 
and to enhanced recognition of IE antigens by CTL. Under 
conditions of selective IE expression, pp89 was presented to 
CTL  in  cells  infected  with  either  wild-type  MCMV  or 
MCMV lacl (Fig. 2 B, time point 0, absence of E transcrip- 
tion).  The same conditions,  as expected from the iel  pro- 
moter control of the lacZ  gene in MCMV-lacl,  resulted in 
/~-gal recognition by/3-gal-spedfic CTL (Fig. 2 B, right,  time 
point  0). 
Figure 2.  Presentation  of  both 
pp89 and ~-gal is prevented  in the 
E phase. (.4) Experimental  design. 
(7~p) Infection  of  cells in the pres- 
ence of the protein synthesis in- 
hibitor CH results in enhanced 
transcription of IE genes. After 
replacement of CH by the inhib- 
itor of transcription Act D,  IE 
mRNA is translated, leading to 
selective  IE protein synthesis  and 
to  presentation  of antigen  IE. 
(Bottom)  After removal  of  CH, the 
synthesized IE proteins activate 
the transcription of E genes until 
Act D is added. Translation of E 
mRNA leads to the synthesis of 
E proteins. This protocol there- 
fore defines the period of E gene 
transcription  required  for synthesis 
of proteins that  inhibit antigen 
presentation  (28). (B) Recognition 
by pp89-specific (filled cycles) or 
B-gal-specific  (open  circles)  CTL of 
MEF cells  infected  with wild-type 
MCMV (left)  or with the recom- 
binant MCMV lacl coding B-gal 
(right) under the conditions sche- 
matically shown in A. Selective 
IE expression  (.4, top) corresponds to the time point 0 h of E gene tran- 
scription. (C) Rate of pp89 and/J-gal  protein synthesis. MEF cells in- 
fected under the two experimental conditions depicted in A with wild- 
type MCMV or recombinant MCMV lacl, as marked, were labeled with 
[3SS]methionine for 40 rain at 6 h p.i. Whole-cell lysates were analyzed 
by PAGE. 
731  del Valet al. If ACt D is not added immediately after removing CH but 
at later times (see Fig. 2 A, bottom), the synthesized IE pro- 
teins activate the transcription of E genes. The duration of 
E gene transcription is defined by the time at which Act D 
is added. Translation  of E mRNA leads to the synthesis of 
E proteins. With this protocol, conditions of limited E gene 
expression  after enhanced IE gene expression  are achieved. 
Note that conditions permissive for E gene expression  (IE 
+  E conditions depicted in Fig. 2 A), were associated with 
inhibited presentation of not only pp89 as described before 
(28), but also of B-gal, and, with comparable kinetics, pre- 
sentation was eventually abolished (Fig.  2, B, right). 
In the case of pp89, protein synthesis continues during 
MCMV E gene expression. When the rate of 3-gal and pp89 
synthesis was analyzed in cells infected with MCMV lacl, 
the decreasing rate of synthesis was found comparable be- 
tween both proteins under IE and under E conditions (Fig. 
2 C). A comparison between cell lines producing significantly 
different amounts of pp89 had revealed that quantitative differ- 
ences do not account for the inhibition of antigen presenta- 
tion (28). Because two completely unrelated antigens are sub- 
jected to the same inhibition of antigen presentation after 
expression as MCMV IE genes, we reasoned that a common 
step in the MHC class I processing and presentation pathway 
is affected by MCMV E gene functions. 
Correct Processing of pp89 in Absence of Antigen Presenta- 
tion.  The MHC class I processing and presentation pathway 
can be subdivided into: (a) proteolytic processing, (b) pep- 
tide transport into the ER, (c) complex formation of MHC 
class I heavy chain, ~/2m and peptide, and (d) transport of 
the trimolecular complex to the cell surface. Proteolytic pro- 
cessing and peptide transport were not amenable to testing. 
Therefore,  the latter steps were analyzed. H-2  a cells infected 
with the vaccinia recombinant MCMV-ieI-VAC express pp89, 
and the naturally processed nonapeptide 16SyPHFMFTNL  176 
is found in cell lysates after acid extraction (31). It coelutes 
with the synthetic nonamer as a single peak in fraction number 
25 of our standard reverse-phase HPLC runs. The biological 
activity of extracted peptides is demonstrated in a standard 
CTL assay, where pp89-specilic  CTL lyse H-2  d cells that 
were incubated with the relevant duted peptide fraction. Cells 
infected with MCMV under IE conditions contained bio- 
logical activity in the expected nonapeptide peak at fraction 
25 and, in addition, also in fraction 23 (Fig. 3 A, top) (Del 
Val et al., manuscript in preparation). No biological activity 
could be recovered from uninfected cells (data not shown). 
Remarkably, when natural peptides were retrieved  from E 
phase-infected cells that did not present the antigen, essen- 
tiaUy the same dution profile of biological activity was ob- 
served (Fig. 3 A, bottom). Thus, there are no qualitative changes 
in the natural peptide composition of infected cells that could 
account for the differences in antigen presentation. 
In addition, the serial dilution of the fractions representing 
the two antigenic peaks revealed no quantitative differences 
between cells that did or did not present antigen regarding 
the content of endogenously processed peptide (Fig. 3 B, top 
and bottom, respectively). Thus, accurate processing of pp89 
did not result in peptide presentation at the cell surface. We 
concluded that MCMV E gene products interfere with an- 
tigen presentation at a step later than processing. 
Naturally Processed Peptides Are Bound to the MHC Class 
I Heavy Chain L ~.  Current evidence  indicates  that  only 
peptides bound by MHC class I molecules are protected from 
complete degradation (41). Accordingly, peptides can be re- 
trieved only from cells that express the presenting MHC class 
I molecule(s).  The conclusion, however, that the processed 
peptides of pp89 were already transported into the ER and 
associated with L d was premature, because, at least after ex- 
ogenous addition to cells, the nonapeptide can effectively bind 
also to the MHC class I molecule K a (42). Thus, it was con- 
ceivable that during the E phase most of the processed pep- 
tides were in fact bound by K a and not by L d, and therefore 
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Figure 3.  Processing and yidd of 
processed peptides is not affected  by 
MCMV E genes. (A) BALB/c MEF 
were infected with MCMV under 
IE (top) or IE +  E (bottom) condi- 
tions, as defined in Fig. 2 A. At 10 
h p.i., acid-soluble molecules were 
extracted and separated first by gel 
filtration chromatography and then 
by reverse-phase HPLC,  using the 
indicated acetonitrile  gradient  for 
ehtion. HPI.C fractions were tested 
in triplicate with pp89-specific  CTL 
for their content of antigenic pep- 
tides. Fractions where major biolog- 
ical activities duted are indicated. 
(B) The antigenic peptides that were 
detected in A  were quantified by 
testing serial dilutions of the corre- 
sponding HPI.C  fractions  in the 
cytolytic assay. The calculated number of infected cells from which peptides were recovered is given on the horizontal axis, and percent specific lysis 
is given on the vertical axis as a measure of the amount of the relevant antigenic peptide.  (Left) Fraction 23, open circles; (right)  fraction 25, filled 
circles; fraction 26, filled triangles. 
732  MHC Class I Molecule Retention by Murine Cytomegalovirus not  available  for  CTL  from  BALB/c mice,  which  do  not 
generate Ka-restricted pp89-specific CTL (28). According to 
this explanation the biological activity of naturally processed 
peptides from E phase-infected cells would become only ap- 
parent, because extracted peptides, liberated from the assumed 
binding to K a, could now be bound by the L d molecules of 
the  target  cells after external  addition. 
To  settle  this  point,  peptides  were acid  extracted  from 
MCMV-infected cells of the H-2  a"a mouse strain.  This strain 
differs  from BALB/c in that  it lacks the gene encoding L a 
(43).  As shown in Fig.  4,  no peptides with biological ac- 
tivity detectable by pp89-specific CTL could be releaved from 
H-2  amz cells expressing IE genes of MCMV,  and there was 
also no activity extractable from H-2  d"a ceils at the E phase 
of infection (not shown). It was therefore concluded that the 
detection of pp89-derived peptide activity reflects quantita- 
tive peptide binding  to L a,  even after E  gene expression. 
Correct Assembly of  MHC Class I Complexes.  Peptides play 
two cooperative roles during the assembly of MHC dass I 
molecules, the folding of the heavy chain that can occur in 
absence  of ~2m,  and  the  stabilization  of preformed  com- 
plexes of heavy chain and ~2m (13, 14). The isolation of pep- 
tide from cells that  express E  genes indicated  correct  pro- 
cessing,  transport  into  the  ER,  and  association  with  L  a 
heavy chains, but not necessarily the formation of the stable 
trimolectdar  complex.  The  MHC  class  I  molecule  L d is 
known for its reduced affinity for B2m and its ddayed transit 
to the cell surface,  where it is expressed at a lower density 
(44). In addition,  many L a heavy chains remain in a confor- 
mation  typical for the lack of B2m association,  suggesting 
a  critical  susceptibility  of L  d heavy chains  during  protein 
folding  (18). 
Therefore,  the amount  and conformational  properties of 
synthesized  L a  molecules  were  compared  after  metabolic 
labding  of  MCMV-infected  cells  representing  both  ex- 
perimental  conditions  (Fig.  5,  top).  Quantitative  immuno- 
precipitations were performed sequentially, starting with the 
mAb 64-3-7,  which detects only L a heavy chains in a con- 
formation  that  is not  associated with ~2m (18).  This anti- 
body precipitated "~90% of the L  a molecules. No quantita- 
tive differences associated with the different phases of MCMV 
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Figure 4.  Absence of processed pp89 peptides in cells lacking L  a. 
H-2  a'~ MEF lacking the L  a gene were infected with MCMV under IE 
conditions, and the acid-soluble  molecules  were extracted at 10 b p.i. and 
analyzed by HPLC. Individual  fractions  were tested  in triplicate  with pp89- 
specific CTL in a cytolytic  assay. 
Figure 5.  Correct  assembly  of MHC class I heavy chain//~2m com- 
ple:~s during E gene  expression. MEF cells  were  MCMV-infected  or mock- 
infected  under the two experimental  conditions indicated (top). Metabolic 
labeling with [3sS]methinnine was carried out at the two time points 
marked (filled box). The period of labeling is indicated below in minutes 
after removal of CH. Cell lysates  were immunoprecipitated sequentially, 
first with mAb 64-3-7 (data not shown), then with mAb 28-14-8s (left), 
and finally with mAb 34-5-8s (right). Each precipitate was subjected  to 
gel electrophoresis. 
gene expression were observed (data not shown). After clearing 
of the cell lysates from excess antibody,  L d molecules were 
precipitated with the c~3 domain-specific mAb 28-14-8s, which 
detects  the  remaining  fl2m-complexed  L d molecules,  and 
separated by SDS-PAGE (Fig.  5, left). L d molecules migrated 
with a relative electrophoretic mobility of 46 kD as a broad 
band that probably included differently glycosylated forms. 
Despite the fact that 64-3-7 + L  a molecules were removed in 
the first precipitation  step, the amount of precipitated 32m 
was still low, perhaps due to the instability of the La/B2m 
complex during the precipitation procedure. Note, however, 
that Ld/fl2m complexes were found in comparable amounts 
under both infection conditions.  Considering the L  d depen- 
dence of peptide isolation,  we thus concluded that  correct 
trimolecular  class  I complexes are also formed in cells that 
are unable  to present  the  antigen. 
In view of the particular properties of L  d, the MHC class 
I  molecule D d was also studied,  which represents  a MHC 
dass I molecule that quantitatively and firmly associates with 
32m,  and  matures  faster.  Again,  the  amount  of D d com- 
plexes remained  constant  after transition  of MCMV infec- 
tion into the E phase (Fig. 5, right).  Remarkably, and different 
from L  d, the D a molecules synthesized at different times of 
MCMV gene expression exhibited a different electrophoretic 
733  del Val et al. mobility. Under mock and IE conditions, several bands were 
found, probably reflecting stages of maturation to forms of 
complex glycosylation. Transition to the E phase, however, 
restricted this pattern to a major band of fast mobility, prob- 
ably representing the glycoprotein precursor. The coprecipi- 
tation of 32m indicated that intracellular assembly  of the 
MHC class I complex was not affected. The fact that not 
only antigen presentation by L  d but also the glycosylation 
of D d was affected suggested a general effect of MCMV E 
gene products on MHC class I heavy chain maturation. 
Defective Glycosylation of MHC Class I Complexes.  To lo- 
cate the effect on the posttranslational modification, the sus- 
ceptibility of MHC class I molecules to Endo H  digestion 
was determined. As it is the case for other glycoproteins, MHC 
class I molecules cotranslationally acquire  a high-mannose 
core of N-linked digosaccharides in the ER. Endo H prefer- 
entially cleaves immature N-linked oligosaccharides  charac- 
teristic of glycoproteins that have not reached the medial-Golgi 
compartment (45). Further processing of the oligosaccharide 
chain by enzymes located in the medial-Golgi compartment 
leads to the fully mature glycoproteins and renders the glycan 
structure resistant  to Endo H  digestion (46). 
Maturation of MHC dass I molecules was studied by pulse- 
chase experiments. A long pulse of 90 min was required to 
follow the fate of newly synthesized L  d molecules because 
the expression of L  d in embryonic fibroblasts is very low (see 
also Fig.  7, top left).  In mock-infected cells and also in IE- 
infected cells (Fig. 6, top/eft), the L  d heavy chains, in agree- 
ment with a previous report (44),  slowly matured to Endo 
H-resistant forms. This was apparent from comparing the 
relative amount of Endo H-susceptible and -resistant forms 
after the pulse at different time points of the chase period. 
Even after a chase period of 270 min, some L  a heavy chains 
remained Endo H susceptible. The decrease in the overall con- 
tent of L  d molecules at that time reflects the instability of 
this molecule and explains the poor surface expression of L  a. 
The comparison between L  d molecules from cells represen- 
ting both infection conditions revealed a clear difference in 
the acquisition of Endo H  resistance. In contrast to the IE- 
infected ceils, the majority of molecules synthesized during 
the E phase (Fig. 6, top right) remained in the Endo H-sensi- 
tive form throughout the chase period, which indicated that 
they had not gained access to the Golgi enzymes. Note, how- 
ever, that in spite of defective maturation, there was no differ- 
ence in the overall stability of L  d molecules. 
Essentially  the  same  result  was  obtained for  D d heavy 
chains. Although this molecule is already completely  processed 
during the 90-min pulse to Endo H-resistant forms under 
mock and IE gene expression conditions (Fig. 6, bottom/eft), 
E gene expression  prevented glycoprotein maturation with 
an efficiency comparable with L  d without affecting protein 
stability  (Fig.  7, bottom right).  Similar results were also ob- 
tained for K a (data  not shown). It has been reported that 
full glycosylation is not a prerequisite for MHC class I mole- 
cule transport and cell surface expression (47). Thus, we con- 
cluded that after expression of MCMV E genes, the correctly 
assembled MHC class I complexes remain Endo H sensitive, 
Figure 6.  E gene expression prevents acquisition of Endo H resistance 
by MHC class I molecules. Mock-infected or MCMV-infected cells were 
treated with CH and Act D as indicated (top).  Cells were pulse labeled 
with [3sS]methionine  for 90 min as indicated (filled box),  and then chased 
(arrows) for the indicated times. Immunoprecipitations  were performed se- 
quentially first with mAb 64-3-7 (data not shown),  then mAb 28-14-8s 
(top), and finally with mAb 34-5-8s (bottom).  Before gel dectrophoresis, 
the marked samples (+) were incubated with Endo H. The bands resulting 
from enzymatic digestion are indicated on the right with s (for suscep- 
tible), or with r  (for resistant). 
either because they do not reach the medial-Golgi compart- 
ment or because they complex with other molecules that pre- 
vent correct glycosylation, as shown for the different glycosy- 
lation of the CD3 ~ chain in cells expressing different forms 
of the TCR (48). 
Defective Transport  of  MHC Class I Molecules.  The surface 
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Figure 7.  FACS  |  analysis of surface glycoprotein expression in the E 
phase of infection. BALB.SV cells were incubated with phosphonoacetic 
acid (A and C) or MCMV infected (/3 and D) for 18 h in the presence 
of phosphonoacetic acid to prevent late-phase gene expression, and then 
stained with mAb 28-14-8s (anti-L  d) and 34-5-8s (anti-D  J) (A and B), or 
with mAb IM7-8.1E4  (anti-CD44), and R17 217.1.3 (anti-CD71) (C and D). 
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tween an MHC class I molecule and an MCMV E protein 
could be compatible with transport to the cell surface. The 
surface density of the MHC class I molecules L  a and D a was 
determined by cytofluorometric analysis at a later stage of 
the E phase, 18 h postinfection,  in order to reveal the fate 
of nascent MHC class I molecules. The E phase arrest was 
achieved by infection of cells with MCMV in the presence 
of phosphonoacetic acid, which blocks viral DNA replica- 
tion and the subsequent  expression of late-phase genes. A 
decrease of L  a and D a molecules to almost undetectable levels 
was observed, impressive in particular for D d, which is more 
abundantly expressed (Fig. 7, compare A and/3). Similar results 
were obtained also for the H-2 proteins K a, Lq, K b, D b, K k, 
and D k (data not shown). In contrast, other glycoproteins, 
like CD71 (transferrin receptor) and the adhesion molecule 
CD44 (pgp-1), essentially remained unaffected by infection 
(Fig. 7, C and D). Under the premise that CD44 and CD71 
have a turnover rate comparable to that of MHC class I mol- 
ecules, these data would imply that MHC class I glycopro- 
teins represent a preferential target for the MCMV E gene 
effect. We concluded that after expression of MCMV E genes 
the correctly assembled MHC class I complexes do not reach 
the medial-Golgi compartment and remain Endo H sensitive. 
Discussion 
We demonstrate that the mechanism of interference by 
MCMV E gene products with antigen presentation  to CTL 
(28) can be described as a block in the intracellular transport 
of MHC class I complexes through the Golgi compartment. 
The dramatic inhibitory effect of MCMV E gene products 
on viral antigen presentation provides a paradigm for the poten- 
tial of a herpes virus to interfere with the recognition of in- 
fected cells by CTL.  CMV persists for life in the infected 
host, and CD8 § T lymphocyte function is the hallmark of 
host control of CMV (reviewed in reference 27). For a virus 
that is under control of the cellular immune response, the 
interference with MHC class I molecule transport is clearly 
the most effective evasion mechanism that can be envisaged. 
Provided that the glycosylation studies correctly define the 
location at which the Golgi transport of MHC class I mole- 
cules is blocked,  the results imply that binding of peptides 
to MHC class I molecules occurs in the ER/c/s-Golgi com- 
partment, and not in subsequent  compartments along the 
secretory pathway. 
When the cascade of MCMV gene expression is restricted 
to IE genes, MCMV-specific CTL detect processed peptides 
that  are derived  from  the MCMV  IE  protein pp89  and 
presented by the MHC class I molecule L  d. Subsequent ex- 
pression of E genes for a short time prevents pp89 presenta- 
tion.  Yet, E gene expression has little effect on pp89  syn- 
thesis, the surface  expression of MHC class I molecules appears 
unchanged when antigen presentation  is prevented, and in- 
fected cells are still recognized by CTL that detect a viral 
E antigen that we could not define in molecular terms. This 
suggested a selective effect on pp89 antigen processing (28). 
In the light of the new evidence provided in this paper, how- 
ever, the mechanism of inhibition is much more general than 
previously thought. 
We report on the following findings. (a) Antigen selec- 
tivity was excluded by insertion of the bacterial gene lacZ 
coding for the enzyme B-gal into the MCMV genome under 
control of the iel promoter. Although both proteins, pp89 
and/3-gal, differ with regard to primary sequence, intracel- 
lular distribution, and function, presentation of  both antigens 
was blocked by MCMV E gene expression.  (b) Naturally 
processed peptides extracted from cells that synthesized pp89 
in presence or absence of E proteins had the same biochem- 
ical properties, and the same amount of biochemical activity 
was retrieved in both cases. Therefore, antigen processing was 
correct in nonpresenting cells, and peptide competition could 
not explain the failure of antigen presentation.  (c) The L  d- 
dependent presence of peptides in nonpresenting cells revealed 
peptide transport into the ER and peptide association with 
the heavy chain, and studies on the conformational proper- 
ties of the heavy chain provided evidence for correct forma- 
tion of the trimolecular complex.  (d) The observation that 
during the E phase of viral infection the nascent heavy chains 
did not acquire resistance to Endo H digestion and did not 
reach the cell surface revealed a block in the normal matura- 
tion and transport of MHC class I molecules. This transport 
block affects selectively MHC class I molecules. 
The fact that we failed to see the general effect on MHC 
class I molecule maturation in the earlier communication (28) 
is easily explained.  We investigated the effect on L  d at the 
time it became apparent. Thus, we determined only the resi- 
dent population of surface-expressed L  a molecules that ap- 
peared normal, whereas the fate of nascent molecules was 
not controlled.  The thoroughness of the antigen presenta- 
tion blockade, however, may be due to characteristic features 
of the L  a surface molecules. It is expressed on the cell sur- 
face at levels three to four times lower than K d and D d, the 
association with B2m is delayed, and the slower maturation 
is documented by a delayed  processing  of the N-linked oligosac- 
charide (44). L  a molecules that are not occupied by peptide 
ligands appear at the cell surface, and external addition of 
peptides to cells can alter the conformation and enhance sur- 
face expression (17, 18). Data of Cliristinck  et al. (49) dem- 
onstrate that as few as 200 MHC class I-peptide complexes 
suf~ce for recognition by CTL in vitro. Therefore, if the trans- 
port blockade were incomplete, the number of exported com- 
plexes might not fall  below the detection threshold for other 
Ld-presented antigens or for other peptide-MHC class I mol- 
ecule complexes. By such a mechanism we now explain the 
escape of an MCMV E antigen from the regulatory effect 
(28). We have observed that a 10ofold  difference  in the amount 
of naturally processed and La-presented peptides can be deci- 
sive for target formation in vitro and for recovery from lethal 
viral infection  in vivo (31). 
A transport block of nascent MHC class I molecules to 
the cell surface, either by treatment with brefeldin A (10, 
11), or by the action of the adenovirus protein E3/19K, pre- 
vents presentation of endogenous antigens.  Reversal of the 
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tion signal of E3/19K (26), respectively, restores presenta- 
tion. In the antigen presentation-deficient  cell mutant T2, 
an ER translocation signal rescues presentation of an endog- 
enous peptide (50). Indirect evidence derived from in vitro 
systems suggests that MHC dass I molecules bind synthetic 
peptides in the same compartment where they bind to B2m 
(12-14). These data demonstrate that nascent MHC class I 
molecules are required for peptide presentation,  but do not 
define the place of peptide charging because  naturally processed 
peptides have not been isolated under conditions of inhibited 
MHC class I molecule transport. If the lack of Endo H resis- 
tance correctly defines the location of the transport block by 
MCMV, then MHC class I molecules residing in the ER/cis- 
Golgi compartment already contain the processed peptides. 
Viral effects on MHC expression and on other cell mem- 
brane proteins relevant for immunosurveiUance have been dis- 
cussed for a number of viruses. Yet, with the exception of 
the adenoviruses, there has been no precise molecular anal- 
ysis (for listing,  see reference 20). The adenoviruses provide 
the example that viruses belonging to the same family can 
use related, but different strategies, such as an effect on MHC 
dass I mRNA processing (21, 22) or on the intraceUular  trans- 
port of MHC class I molecules (23-25). 
For the understanding of CMV infection and disease, it 
has been a matter of debate whether, in addition to profiting 
from host conditions  of defective cellular immune control, 
the virus itself has evolved strategies to evade immunosur- 
veillance even in the immunocompetent host. Grundy et al. 
(51) reported that human CMV (HCMV) binds exogenous 
~2m, perhaps masking the virus against the detection by an- 
tibodies, Remarkably, HCMV contains an open reading flame 
(UL18) encoding a glycoprotein with sequence similarity to 
MHC class I molecules (52). Upon expression by a recom- 
binant vaccinia virus, the UL18 gene product can complex 
with 32m (53). The latter authors observed that in HCMV- 
infected cells no synthesis of mature HLA class I molecules 
occurred despite unchanged mRNA levels. Although expres- 
sion of the UL18 gene product has not yet been detected in 
HCMV-infected cells, this led them to speculate that a func- 
tion of the HLA homologue could be to  sequester 32m, 
making it unavailable to nascent cellular class I heavy chains. 
Sequestration of Bzm would result in a block of peptide pre- 
sentation by MHC class I molecules and predict an escape 
from cellular immune control. In MCMV the mechanisms 
are clearly different. We did not see an inhibition of MHC 
class I molecule assembly, and only at a later stage was the 
maturation of the trimolecular complex inhibited. In this con- 
text it is worth mentioning that it was recently observed in 
HCMV-infected cells that HLA dass I molecules were syn- 
thesized but remained retained intracellularly (J. E. Grundy, 
personal communication). 
Why is the full glycosylation of assembled ternary com- 
plex impaired  subsequent  to the expression of MCMV E 
genes? A retention signal is contained within the six COOH- 
terminal amino acids of the E3/19K protein of adenovirus 
2 (56) and mediates the EK/c/s-Golgi retention of complexes 
between E3/19K and MHC dass I molecules (23) reflected 
by the Endo H sensitivity of MHC molecules (24, 25). Al- 
though representing an attractive speculation, the inhibitory 
MCMV protein must not necessarily represent a functional 
homologue of the E3/19K protein. Unlike in adenovirus, no 
complex formation could be detected under comparable ex- 
perimental conditions (24) between an MCMV E protein and 
the nascent  MHC  molecules.  The other possibility,  that 
MCMV E gene products interact with glycosyl transferases, 
was considered unlikely because other glycoproteins reach the 
surface and are correctly glycosylated (H. Hengel, unpub- 
lished data). The rate-limiting step of glycoprotein transport 
appears to be the acquisition of the correct tertiary and quar- 
ternary structure, and improperly folded molecules and pro- 
teins in intermediate stages of folding are retained in the ER 
or in c/s-Golgi compartment (57-59). Particularly, unassem- 
bled MHC dass I molecules are retained in a recycling  pathway 
between the ER and c/s-Golgi compartment (60). With the 
available antibodies we have not detected any effect of MCMV 
on the assembly of the ternary complex.  Degen and Wil- 
liams (61) recently described an 88-kD protein that partici- 
pates in the biogenesis of MHC class I molecules. This pro- 
tein binds  to  the heavy chains  and dissociates when the 
assembled heavy chain-fl2m  complex reaches the medial- 
Golgi compartment and acquires resistance to Endo H diges- 
tion. It is worth studying whether the 88-kD protein is still 
bound to this complex, because its dissociation should not 
be triggered by peptide binding but by some other, later event. 
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